Shots: Cheplapharm to pay AstraZeneca a total of $400M non-contingent consideration, present value recognised as other operating income upon completion of the transaction, anticipated during the Q4’2020. $250M (of the […]readmore
Tags : Cheplapharm
Shots: Takeda will receive $562M up front for divesting its non-core prescription pharmaceutical products targeting a variety of therapeutic categories sold predominantly in the EU and Canada The divested portfolio […]readmore
Shots: AstraZeneca to receive $35M upfront with future sales-contingent payments of up to $6M and it continues to manufacture and supply Seroquel and Seroquel XR to Cheplapharm during a transition […]readmore
Shots: AstraZeneca to receive $178M up front and up to $61M as sales-contingent payments while it continues to manufacture and supply Seroquel and Seroquel XR to Cheplapharm during a transition […]readmore
Shots: AstraZeneca to receive upfront, $243M on completion of the agreement with ~33M as a commercial milestone in 2021 and 2022. Cheplapharm to get global commercial rights for Losec & […]readmore